Alternatively or additionally, an isolated amino acid sequence is provided containing the sequence of one of heavy chains as set forth in FIG.s 1 and 2.

[0016] As a further aspect of the present invention, an isolated humanized antibody or antigen-binding fragment is provided that specifically binds an epitope comprising the amino acid sequence DQGGYT (SEQ ID NO. 9). The antibody or antigen-binding fragment may contain CDRs of the VH and VL regions are from a donor antibody. In some embodiments, the antibody comprises an Fc region, such as the Fc region is of IgGl, IgG2, IgG3, IgG4 or variant thereof. The Fc region may be a human IgG4 or variant thereof, such a human IgG4 containing the S241P hinge stabilizing mutation. The antibody can comprise a light chain constant region of human isotype kappa or variants thereof. In some embodiments, the antibody or fragment is scFv or Fab. In some embodiments, the antibody or fragment is a humanized antibody or fragment or a chimeric antibody or fragment. The antibody or fragment may be a monoclonal antibody. The antibody or fragment may be a bispecific antibody or antigen-binding fragment where one arm of the antibody or fragment specifically binds an epitope comprising the amino acid sequence DQGGYT (SEQ ID NO. 9). In some embodiments, an immunoconjugate is provided comprising one of the foregoing antibodies or fragments linked to a detectable or therapeutic moiety.

[0017] As another aspect, an isolated humanized antibody or antigen-binding fragment is provided that specifically binds an epitope comprising the amino acid sequence GYTMHQDQ (SEQ ID NO. 10). The antibody or fragment can have CDRs of the VH and VL regions from a donor antibody. In some embodiments, the antibody or fragment comprises an Fc region, such as an Fc region of IgG1, IgG2, IgG3, IgG4 or a variant thereof. The Fc region may be a human IgG4 and variants thereof containing the S241P hinge stabilizing mutation. The antibody may comprise a light chain constant region. In some embodiments, the antibody or fragment is an scFv or Fab. A bispecific antibody or antigen-binding fragment is also provided where one arm of the antibody specifically binds an epitope comprising the amino acid sequence GYTMHQDQ (SEQ ID NO. 10). In some embodiments, an immunoconjugate comprising any of the foregoing antibodies or fragments is linked to a detectable or therapeutic moiety.

[0017a] In one aspect, there is provided the use of one or more antibodies or fragments as described herein, in the manufacture of a medicament for preventing or treating a tauopathy, wherein the antibodies or antigen-binding fragment are to be administered under conditions and in an amount effective to prevent or treat the tauopathy.

[0017b] In one aspect, there is provided the use of an anti-tau antibody or fragment in the manufacture of a medicament for treating a tauopathy, wherein the antibody or antigen-binding fragment specifically binds tau and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein each of the VH and VL regions have a sequence selected from amino acid sequences set forth in FIG. 1 and 2, and the antibody or fragment is to be administered in a dose of from about 0.1 mg/kg to about 250 mg/kg to the subject.

[0018] As a further aspect of the present invention, a method of preventing or treating a tauopathy in a subject, comprising administering to a human in need of therapy for a tauopathy with one or more of the antibodies or fragments described herein. The antibodies or antigen-binding fragment are administered under conditions and in an amount effective to prevent or treat the tauopathy. The tauopathy may be one or more of Alzheimer's disease

15. The antibody or fragment of claim 1, wherein the antibody or fragment binds human tau protein with an equilibrium dissociation constant (Kd) of at least 10^{-4}M.

16. A multi-specific antibody or antigen-binding fragment having a plurality of antigen-binding regions, wherein at least one antigen-binding region of the multi-specific antibody or fragment binds to human tau protein.

17. A bispecific antibody or antigen-binding fragment having two antigen-binding regions, wherein one of the antigen-binding regions of the bispecific antibody or fragment binds to human tau protein.

18. A bispecific antibody or antigen-binding fragment where one arm of the antibody or antigen-binding fragment competes with HJ8.5 for specific binding to human tau protein.

19. A bispecific antibody or antigen-binding fragment where one arm of the antibody or antigen-binding fragment is comprised of a heavy chain variable (VH) region and a light chain variable (VL) region, wherein each of the VH and VL regions have a sequence selected from amino acid sequences set forth in FIG. 1 and 2.

20. An antibody or antigen-binding fragment as in any of claims 1 to 19 further comprising a toxic payload, optionally a drug conjugate.

21. An antibody or antigen-binding fragment as in any of claims 1 to 19 further comprising a radionuclide.

22. An isolated nucleic acid molecule encoding an antibody or antigen-binding fragment of any of claims 1 to 21 or a VH region or VL region set forth in FIG.s 1 or 2.

23. A vector comprising the nucleic acid molecule of claim 22.

24. The vector of claim 23, wherein the vector is an expression vector.

25. An isolated host cell comprising the vector of claim 22.

26. The host cell of claim 25, wherein the cell is a prokaryotic or eukaryotic cell.

27. The host cell of claim 26, wherein the cell is a mammalian cell.

28. A pharmaceutical composition comprising an antibody or antigen-binding fragment of any of claims 1 to 21 and a pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising the nucleic acid molecule of claim 22 and a pharmaceutically acceptable carrier.

30. Use of one or more antibodies or fragments of claim 1, in the manufacture of a medicament for preventing or treating a tauopathy, wherein the antibodies or antigen-binding fragment are to be administered under conditions and in an amount effective to prevent or treat the tauopathy.

31. The use of claim 30, where the tauopathy is one or more of Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease (PiD), a group of related disorders collectively termed frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), amyotropic lateral sclerosis (ALS), Creutzfeldt-Jakob disease (CJD), dementia pugilistica (DP), Gerstmann-Straussler-Scheinker disease (GSSD), Lewy body disease, chronic traumatic encephalopathy (CTE), or Huntington disease.

32. An isolated amino acid sequence containing the sequence of one of the light chains as set forth in FIG.s 1 and 2.

33. An isolated humanized antibody or antigen-binding fragment that specifically binds an epitope comprising the amino acid sequence DQGGYT (SEQ ID NO. 9).

34. The antibody or antigen-binding fragment of claim 33, wherein CDRs of the VH and VL regions are from a donor antibody.

35. The antibody or antigen-binding fragment of claim 33, wherein the antibody comprises an Fc region.

36. The antibody or antigen-binding fragment of claim 35, wherein the Fc region is of IgGl, IgG2, IgG3, IgG4 or variant thereof.

37. The antibody or antigen-binding fragment of claim 35, wherein the Fc region is a human IgG4 and variants thereof.

38. The antibody or antigen-binding fragment of claim 35, wherein the Fc region is a human IgG4 containing the S241P hinge stabilizing mutation.

39. The antibody or antigen-binding fragment of claim 33, wherein the antibody comprises a light chain constant region.

40. The antibody or antigen-binding fragment of claim 39, wherein the light chain constant region is of isotype lambda and variants thereof.

41. The antibody or antigen-binding fragment of claim 33, wherein the fragment is an scFv or Fab.

42. A bispecific antibody or antigen-binding fragment where one arm of the antibody or fragment specifically binds an epitope comprising the amino acid sequence DQGGYT (SEQ ID NO. 9).

43. An immunoconjugate comprising an antibody or fragment according to claim 33 linked to a detectable or therapeutic moiety.

44. An isolated humanized antibody or antigen-binding fragment that specifically binds an epitope comprising the amino acid sequence GYTMHQDQ (SEQ ID NO. 10).

45. The antibody or antigen-binding fragment of claim 44, wherein CDRs of the VH and VL regions are from a donor antibody.

46. The antibody or antigen-binding fragment of claim 44, wherein the antibody comprises an Fc region.

47. The antibody or antigen-binding fragment of claim 46, wherein the Fc region is of IgG1, IgG2, IgG3, IgG4 or variant thereof.

48. The antibody or antigen-binding fragment of claim 46, wherein the Fc region is a human IgG4 and variants thereof.

49. The antibody or antigen-binding fragment of claim 46, wherein the Fc region is a human IgG4 containing the S241P hinge stabilizing mutation

50. The antibody or antigen-binding fragment of claim 44, wherein the antibody comprises a light chain constant region.

51. The antibody or antigen-binding fragment of claim 44, wherein the fragment is an scFv or Fab.

52. A bispecific antibody or antigen-binding fragment where one arm of the antibody specifically binds an epitope comprising the amino acid sequence GYTMHQDQ (SEQ ID NO. 10).

53. An immunoconjugate comprising the antibody or fragment of claim 44 linked to a detectable or therapeutic moiety.

54. An isolated amino acid sequence containing the sequence of one of heavy chains as set forth in FIG.s 1 and 2.

55. Use of an anti-tau antibody or fragment in the manufacture of a medicament for treating a tauopathy, wherein the antibody or antigen-binding fragment specifically binds tau and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein each of the VH and VL regions have a sequence selected from amino acid sequences set forth in FIG. 1 and 2, and the antibody or fragment is to be administered in a dose of from about 0.1 mg/kg to about 250 mg/kg to the subject.

56. The use of claim 55, wherein the dose of the antibody or fragment is from about 1 mg/kg to about 25 mg/kg.

57. The use of claim 55, wherein the antibody or fragment has a VL region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3 and 4 [VK1, VK2, VK3, and VK4].

58. The use of claim 55, wherein the antibody or fragment has a VH region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5, 6, 7 and 8 [VH1, VH2, VH3, and VH4].

59. The antibody of claim 6, wherein the Fc region is a human IgG4 or variant thereof.